• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Top FDA Brass Weigh in on Regulatory Safeguards in COVID-19 Vaccine Trials

Top FDA Brass Weigh in on Regulatory Safeguards in COVID-19 Vaccine Trials

August 10, 2020

Three top FDA officials, including Commissioner Stephen Hahn, last week shared with their medical peers the agency’s primary considerations when reviewing COVID-19 vaccine trials, reassuring them that these vaccine candidates would face the same level of scrutiny as all other FDA-approved products.

Hahn, along with Center for Biologics Evaluation and Research Director Peter Marks and Deputy Commissioner for Medical and Scientific Affairs Anand Shah, wrote in an opinion piece published on the Journal of the American Medical Association website that the physician leaders of the agency “unequivocally state that candidate COVID-19 vaccines will be reviewed according to the established legal and regulatory standards for medical products.”

In the case of COVID-19 vaccine candidates specifically, the FDA will focus on three factors, the officials say. First, it will ensure that any vaccine is manufactured in accordance with all of FDA’s quality standards and that its safety and effectiveness are verified.

Second, to be effective in a widespread population, the agency is stressing the need for COVID-19 vaccine sponsors to focus on populations disproportionately affected by the pandemic, including racial and ethnic minorities, older adults and people with medical comorbidities. “Inclusion of diverse populations, including older individuals, in trials is necessary for a comprehensive assessment of product safety and effectiveness and to properly inform clinical decision-making,” the officials wrote.

Sponsors also should consider additional trial safeguards for special populations, such as children and pregnant women, to guarantee they can be included safely in trials, they say.

Third, the FDA will discuss with sponsors their plans for postmarket surveillance of vaccines that are approved before a large volume of safety evidence is available.

The authors also note that current vaccine trial enrollments of 15,000 to 20,000 far exceed the FDA benchmark of more than 3,000 patients needed to build a reliable safety database.

To read the article, click here: https://bit.ly/2PLYyBT.

COVID-19
    • Related Directories

      Olumiant (baricitinib)

      Veklury (remdesivir)

      Comirnaty (COVID-19 Vaccine, mRNA)

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing